G
Advances candidate products from the laboratory to the clinic; develops manufacturing processes and tests that provide material for Phase I/II clinical trials, with emphasis on techniques suitable for large-scale manufacture of vaccines; produces vaccine components at VRC facilities and through contract agreements and a cGMP pilot plant that is currently under construction in Frederick, MD; and ensures the timelines of vaccine projects selected for clinical trial evaluation, prepares regulatory submissions, and develops appropriate pre-clinical testing for all vaccine products.
The requested service contract is for the Sequencing Core instrument, the ZEPHYR Workstation. This contract is needed to ensure that these two instruments are functioning properly. These machines are used to generate library sequences originating from tissues from phenotypically sorted cells from a variety of tissues. The Place of performance is 9000 Rockville Pike, Bethesda, MD 20892.
The statutory authority for this sole source requirement is 41 U.S.C.1901 (e) (2) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide comparable services may submit a capability statement that will be considered by email (subject line to reference NOI-NIAID-1933393) to Laura Grey at [email protected], by 5:00 pm eastern standard time 5:00 PM eastern standard time, October 10, 2018. All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.